the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration

The Filatov Institute of Eye Diseases and Tissue Therapy30 enrolled

Overview

To evaluate the status of the blood-aqueous barrier by objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP) in patients with exudative age-related macular degeneration (AMD) undergoing anti-angiogenic therapy.

All patients were assigned to two groups. The first group was administered intravitreal injections of 2 mg (0.05 mL) aflibercept, while the second group received 6 mg (0.05 mL) brolucizumab. The regimen of treatment in both groups was treat-and-extend

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

AMD

Interventions

laser flare photometry before intravitreal injectionDIAGNOSTIC_TEST

The first group was administered intravitreal injections of 2 mg (0.05 mL) aflibercept The second group received 6 mg (0.05 mL) brolucizumab. Objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP).

Eligibility

Sex: ALLMin age: 47 YearsMax age: 88 Years

Medical Language ↔ Plain English

Inclusion Criteria: only primary, untreated patients with exudative AMD who were eligible for anti-VEGF therapy were included in the study. - Exclusion Criteria:patients with hyperlipidemia, cardiac or renal insufficiency, ocular neoplasms, glaucoma, as well as those with corneal opacity within the optical zone or any inflammation of the studied eye that could lead to increased light-scattering intensity of protein molecules in the anterior chamber fluid, as measured by laser flare photometry, were excluded from the study. \-

Locations (1)

The Filatov Institute of Eye Diseases and Tissue Therapy

Odesa, Ukraine

Outcomes

Primary Outcomes

laser flare photometry values in the aqueous humor

Detection of protein concentration in the aqueous humor using laser flare photometry

Time frame: 6-month

Secondary Outcomes

best-corrected visual acuity

the change in best-corrected visual acuity (BCVA)

Time frame: 6-month

central retinal thickness

central retinal thickness (CRT)

Time frame: 6-month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.